Cencora is a medical distribution company located in Pennsylvania, United States, which is part of the Healthcare sector, and is traded under the ticker COR on the NYSE exchange.
Cencora stock last closed at $244.53, up 0.39% from the previous day, and has increased 5.77% in one year. It has underperformed other stocks in the Medical Distribution industry by 0.06 percentage points. Cencora stock is currently +13.86% from its 52-week low of $214.77, and -6.76% from its 52-week high of $262.26.
At the moment, there are 193.92M shares of COR outstanding. The market value of COR is $47.42B. In the last 24 hours, 1.82M COR shares were traded.
How to Buy Cencora Stock
Not sure how to invest in Cencora stock? Here's how.
Decide where to buy Cencora stock: You need to pick a stock brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Cencora stock.
Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Fund your investment account: Choose your payment method and add your info.
Evaluate Cencora stock: The Cencora ticker symbol is COR. Is Cencora stock a good investment? Should you buy shares of COR? How do COR's underlying business fundamentals look? Do top analysts think Cencora is a good buy? Why has COR's stock price moved recently? (Hint: Our stock market research website can help you figure out if COR is a good stock to buy).
Make your COR buy order: Decide if you will purchase COR shares at the current market price or use a limit order to purchase COR stock at a particular price.
Keep an eye on your COR investment: Create a watchlist to track your new investment in Cencora stock.
Step 1: Decide where to buy Cencora stock
You need a brokerage account in order to access the NYSE market and buy COR stock.
A brokerage account is an investment account that allows you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to world markets: From Technology to Financial Services, New York to London — you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by signing up for an account with eToro today.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've selected the right brokerage, you'll need to fill out some personal info so you are able to buy COR today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Cencora stock
Once you have decided on the best place to buy Cencora stock, it's absolutely critical to analyze their stock before you invest, so you actually comprehend the risk and upside.
Cencora shares at a glance
COR Price
$244.53
1w %
-0.65%
1y %
5.77%
5y %
158.71%
P/E
34.39x
P/B
209.28x
P/S
0.16x
PEG
0.92x
Revenue
$303.19B
Earnings
$1.40B
Fore. Rev. Growth
6.44%
Fore. Earn. Growth
37.44%
Market Cap
$47.42B
Next Earnings
N/A
Next Dividend
Mar 3, 2025
Cencora Due Diligence Score
WallStreetZen was created to help average investors do more accurate fundamental analysis.
You can see all of the due diligence checks on COR's stock page.
Is COR stock overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge COR's true value.
Using relative valuations methods:
COR may be overvalued based on its P/E ratio of 34.39x, relative to Medical Distribution industry P/E ratio of 28.62x
COR may be undervalued based on its P/B ratio of 209.28x, relative to Medical Distribution industry P/B ratio of -601.13x
COR could be undervalued based on its PEG ratio of 0.92x
COR has cash burn of 638103000. It has enough cash and short-term investments to cover this for at least one year.
There are more short-term assets than long-term liabilities on the COR balance sheet.
COR has $3.22B in cash and short term investments. This is sufficient to cover its annual cash burn of $638.10M.
Failed Financial Due Diligence Checks:
Total COR debt is higher than 5 years ago, relative to shareholder equity.
COR profit margin has gone down from 0.7% to 0.5% in the past year.
COR has a relatively high debt to equity ratio of 303.17.
There are more short-term liabilities than short-term assets on the COR balance sheet.
Is COR stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 8 Wall Street analysts who give recommendations on COR, the consensus analyst rating on Cencora is a Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest COR Analyst Forecasts
Stephanie Davis, a bottom 4% analyst from Barclays maintains COR with a strong buy rating and raises their COR price target from $263.00 to $290.00, on Nov 7, 2024.
Michael Cherny, a top 14% analyst from Leerink Partners maintains COR with a buy rating and lowers their COR price target from $277.00 to $275.00, on Oct 7, 2024.
Michael Funk, a top 49% analyst from Bank of America downgrades COR to a hold rating and lowers their COR price target from $275.00 to $245.00, on Sep 18, 2024.
You can dig deeper into what analysts are forecasting on the Cencora stock forecast page.
COR Technical Indicators
SMA10
248.88
SMA20
249.23
SMA50
239.91
SMA100
237.2
SMA200
234.03
MACD
1.86
MACD Signal
3.35
MACD Histogram
-1.49
RSI
48.21
Stochastic %K
12.31
Stochastic %D
15.05
StochRSI %K
2.42
StochRSI %D
2.37
COR Performance Metrics
Last year, COR earnings were $1.40B. During the last five year, COR's earnings have increased by 18.06% per year. This was slower than the Medical Distribution industry average of 57.32%.
Last year, COR revenue was $303.19B. In the last 5 year, COR's revenue has increased by 10.74% per year. This was faster than the Medical Distribution industry average of 9.02%.
Cencora pays a dividend of 0.64%, compared to the Medical Distribution industry's average dividend yield of 1.2%. If you owned $1,000 of COR stock, you would have been paid $6.42 last year.
Cencora dividend payments have consistently grown over the past decade and have remained stable.
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your COR buy order
There are two main options:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are usually the best for newer investors.
Limit order: A limit order enables you to buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a given dollar amount, use a limit order.
Hit the Open Trade button and your broker will execute the order.
If you want additional help investing in stocks on eToro, click the helpful video below:
As of Feb 13, 2025, it costs $244.53 to buy one share of Cencora stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.409 shares of COR.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.